Samik Pharmaceutica Secures Potential for Monthly Long-Acting Injection of Thymosin Alpha 1
Samik Pharmaceutica has secured technology for developing an injection that releases Thymosin Alpha 1 over an extended period in the body, presenting the possibility of developing a formulation with improved dosing convenience. **Use of Biodegradable Polymer Microspheres… Controlling In-Vivo Releas

Samik Pharmaceutica has secured technology for developing an injection that releases Thymosin Alpha 1 over an extended period in the body, presenting the possibility of developing a formulation with improved dosing convenience.
Use of Biodegradable Polymer Microspheres… Controlling In-Vivo Release Rate Is Key
The technology is designed to encapsulate Thymosin Alpha 1 in biodegradable polymer microspheres, which are then administered into the body so that the drug is released slowly over a set period. The key lies in controlling the in-vivo release rate, moving beyond simply injecting the drug. The biodegradable polymer microspheres act as a delivery vehicle carrying the drug, with a structure applied that releases the drug over a fixed period.
Existing Aqueous Formulation Requires Repeated Subcutaneous Injections… "Potential for Monthly Dosing Secured"
The existing aqueous formulation had the limitation of requiring repeated subcutaneous injections for drug administration. Samik Pharmaceutica expanded its development potential in the direction of reducing dosing frequency by applying long-acting technology that extends the drug release period.
The company explained that, based on this technology, it has secured the potential to develop a long-acting injectable that can be administered once monthly. If it leads to actual product development, it could be used to reduce the burden of repeated dosing and improve dosing convenience for patients.
Still at the 'Development Potential' Stage… Commercialization, Clinical, and Approval Plans Unconfirmed
However, what has been presented so far is merely the stage of securing the possibility of developing a long-acting injectable. Whether a monthly-dose product will actually be commercialized, along with specific development timelines, clinical trial plans, and regulatory approval plans, remains unconfirmed. If Samik Pharmaceutica materializes this technology into an actual drug development stage, the points to be confirmed going forward will likely include the drug release duration, stability, efficacy, and the progress of clinical development and approval.
[This article is for informational purposes only as reference material for investment decisions and does not recommend the purchase or sale of any specific asset or guarantee investment returns. The final judgment and responsibility for investments rest with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



